Only a few weeks after ConcertAI inked a deal with Bristol-Myers Squibb, it has signed a similar deal with Pfizer. The commonality is ConcertAI focuses on oncology-specific Real-World Data (RWD) and advanced AI for Real-World Evidence (RWE) generation, an area of increased interest for biopharma companies.